1. Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic assault in a population-based examine. Stroke. 2005;36:720-723. doi: 10.1161/01.STR.0000158917.59233.b7
2. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Sufferers With Stroke and Transient Ischemic Assault: A Guideline From the American Coronary heart Affiliation/American Stroke Affiliation. Stroke. 2021;52:e364-e467. doi: 10.1161/STR.0000000000000375
3. Easton JD, Saver JL, Albers GW, et al. Definition and analysis of transient ischemic assault: a scientific assertion for healthcare professionals from the American Coronary heart Affiliation/American Stroke Affiliation Stroke Council; Council on Cardiovascular Surgical procedure and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Illness. The American Academy of Neurology affirms the worth of this assertion as an academic device for neurologists. Stroke. 2009;40:2276-2293. doi: 10.1161/STROKEAHA.108.192218
4. Thacker EL, Wiggins KL, Rice KM, et al. Quick-term and long-term threat of incident ischemic stroke after transient ischemic assault. Stroke. 2010;41:239-243. doi: 10.1161/STROKEAHA.109.569707
5. Hill MD, Yiannakoulias N, Jeerakathil T, et al. The excessive threat of stroke instantly after transient ischemic assault: a population-based examine. Neurology. 2004;62:2015-2020. doi: 10.1212/01.wnl.0000129482.70315.2f
6. Giles MF, Albers GW, Amarenco P, et al. Early stroke threat and ABCD2 rating efficiency in tissue- vs time-defined TIA: a multicenter examine. Neurology. 2011;77:1222-1228. doi: 10.1212/WNL.0b013e3182309f91
7. Cucchiara BL, Kasner SE. All sufferers must be admitted to the hospital after a transient ischemic assault. Stroke. 2012;43:1446-1447. doi: 10.1161/STROKEAHA.111.636746
8. Amarenco P. Not all sufferers must be admitted to the hospital for commentary after a transient ischemic assault. Stroke. 2012;43:1448-1449. doi: 10.1161/STROKEAHA.111.636753
9. Amort M, Fluri F, Schäfer J, et al. Transient ischemic assault versus transient ischemic assault mimics: frequency, medical traits and end result. Cerebrovasc Dis. 2011;32:57-64. doi: 10.1159/000327034
10. Hand PJ, Kwan J, Lindley RI, et al. Distinguishing between stroke and mimic on the bedside: The Mind Assault Research. Stroke. 2006;37:769-775. doi: 10.1161/01.STR.0000204041.13466.4c
11. Shah KH, Edlow JA. Transient ischemic assault: evaluation for the emergency doctor. Ann Emerg Med. 2004;43:592-604. doi: 10.1016/S0196064404000058
12. Crisostomo RA, Garcia MM, Tong DC. Detection of diffusion-weighted MRI abnormalities in sufferers with transient ischemic assault: correlation with medical traits. Stroke. 2003;34:932-937. doi: 10.1161/01.STR.0000061496.00669.5E
13. Adams HP Jr, del Zoppo G, Alberts MJ, et al; ; ; ; ; . Pointers for the early administration of adults with ischemic stroke: a tenet from the American Coronary heart Affiliation/American Stroke Affiliation Stroke Council, Scientific Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Illness and High quality of Care Outcomes in Analysis Interdisciplinary Working Teams: the American Academy of Neurology affirms the worth of this guideline as an academic device for neurologists. Stroke. 2007;38:1655-1711. doi: 10.1161/STROKEAHA.107.181486
14. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to foretell very early stroke threat after transient ischaemic assault. Lancet. 2007;369:283-292. doi: 10.1016/S0140-6736(07)60150-0
15. Cucchiara BL, Messe SR, Taylor RA, et al. Is the ABCD rating helpful for threat stratification of sufferers with acute transient ischemic assault? Stroke. 2006;37:1710-1714. doi: 10.1161/01.STR.0000227195.46336.93
16. Amarenco P, Lavallée PC, Labreuche J, et al; . One-year threat of stroke after transient ischemic assault or minor stroke. N Engl J Med. 2016;374:1533-1542. doi: 10.1056/NEJMoa1412981
17. Wu CM, McLaughlin Okay, Lorenzetti DL, et al. Early threat of stroke after transient ischemic assault: a scientific evaluation and meta-analysis. Arch Intern Med. 2007;167:2417-2422. doi: 10.1001/archinte.167.22.2417
18. Rothwell PM, Warlow CP. Timing of TIAs previous stroke: time window for prevention could be very quick. Neurology. 2005;64:817-820. doi: 10.1212/01.WNL.0000152985.32732.EE
19. Kernan WN, Ovbiagele B, Black HR, et al; American Coronary heart Affiliation Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Scientific Cardiology, Council on Peripheral Vascular Illness. Pointers for the prevention of stroke in sufferers with stroke and transient ischemic assault: a tenet for healthcare professionals from the American Coronary heart Affiliation/American Stroke Affiliation. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024
20. Rothwell PM, Giles MF, Chandratheva A, et al. Impact of pressing remedy of transient ischaemic assault and minor stroke on early recurrent stroke (EXPRESS examine): a potential population-based sequential comparability. Lancet. 2007;370:1432-1442. doi: 10.1016/S0140-6736(07)61448-2
21. Hackam DG, Spence JD. Antiplatelet remedy in ischemic stroke and transient ischemic assault: an outline of main trials and meta-analyses. Stroke. 2019;50:773-778. doi: c10.1161/STROKEAHA.118.023954
22. Bhatia Okay, Jain V, Aggarwal D, et al. Twin antiplatelet remedy versus aspirin in sufferers with stroke or transient ischemic assault: meta-analysis of randomized managed trials. Stroke. 2021;52:e217-e223. doi: 10.1161/STROKEAHA.120.033033
23. Wang Y, Pan Y, Zhao X, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic assault (CHANCE) trial: one-year outcomes. Circulation. 2015;132:40-46. doi: 10.1161/CIRCULATIONAHA.114.014791
24. Furie KL, Kasner SE, Adams RJ, et al; . Pointers for the prevention of stroke in sufferers with stroke or transient ischemic assault: a tenet for healthcare professionals from the American Coronary heart Affiliation/American Stroke Affiliation. Stroke. 2011;42:227-276. doi: 10.1161/STR.0b013e3181f7d043
25. Powers WJ, Rabinstein AA, Ackerson T, et al; American Coronary heart Affiliation Stroke Council. 2018 Pointers for the Early Administration of Sufferers With Acute Ischemic Stroke: a tenet for healthcare professionals from the American Coronary heart Affiliation/American Stroke Affiliation. Stroke. 2018;49:e46-e110. doi: 10.1161/STR.0000000000000158
26. O’Donnell MJ, Chin SL, Rangarajan S, et al; INTERSTROKE Investigators. International and regional results of probably modifiable threat elements related to acute stroke in 32 international locations (INTERSTROKE): a case-control examine. Lancet. 2016;388:761-775. doi: 10.1016/S0140-6736(16)30506-2
27. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in sufferers with kind 2 diabetes: a scientific evaluation and meta-analysis of cardiovascular end result trials. Lancet Diabetes Endocrinol. 2019;7:776-785. doi:10.1016/S2213-8587(19)30249-9
28. Bertoccini L, Baroni MG. GLP-1 receptor agonists and SGLT2 inhibitors for the remedy of kind 2 diabetes: new insights and alternatives for cardiovascular safety. Adv Exp Med Biol. 2021;1307:193-212. doi:10.1007/5584_2020_494
29. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in sufferers with kind 2 diabetes and acute coronary syndrome N Engl J Med. 2015;373:2247-2257. doi: 10.1056/NEJMoa1509225
30. Sheahan KH, Wahlberg EA, Gilbert MP. An summary of GLP-1 agonists and up to date cardiovascular outcomes trials. Postgrad Med J. 2020;96:156-161. doi:10.1136/postgradmedj-2019-137186
31. Kim AS. Medical administration for secondary stroke prevention. Continuum (Minneap Minn). 2020;26:435-456. doi:10.1212/CON.0000000000000849
32. Smith L, Chakraborty D, Bhattacharya P, et al. Publicity to hypoglycemia and threat of stroke. Ann N Y Acad Sci. 2018;1431:25-34. doi:10.1111/nyas.13872
33. Amarenco P, Bogousslavsky J, Callahan A third, et al; . Excessive-dose atorvastatin after stroke or transient ischemic assault. N Engl J Med. 2006;355:549-559. doi:10.1056/NEJMoa061894
34. Castilla-Guerra, L, Fernandez-Moreno M, Leon-Jimenez D, et al. Statins in ischemic stroke prevention: what have we realized within the post-SPARCL (The Stroke Prevention by Aggressive Discount in Ldl cholesterol Ranges) decade? Curr Deal with Choices Neurol. 2019;21:22. doi: 10.1007/s11940-019-0563-4
35. Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of stroke with the addition of ezetimibe to statin remedy in sufferers with acute coronary syndrome in IMPROVE-IT (Improved Discount of Outcomes: Vytorin Efficacy Worldwide Trial). Circulation. 2017;136:2440-2450. doi:10.1161/CIRCULATIONAHA.117.029095
36. Moritsugu KP. The 2006 report of the Surgeon Normal: the well being penalties of involuntary publicity to tobacco smoke. Am J Prev Med. 20067;32:542-543. doi: 10.1016/j.amepre.2007.02.026
37. Wolf PA, D’Agostino RB, Kannel WB, et al. Cigarette smoking as a threat issue for stroke: the Framingham Research. JAMA. 1988;259:1025-1029.
38. Goldstein LB, Adams R, Alberts MJ, et al. Main prevention of ischemic stroke: a tenet from the American Coronary heart Affiliation/American Stroke Affiliation Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Illness Interdisciplinary Working Group; Cardiovascular Nursing Council; Scientific Cardiology Council; Diet, Bodily Exercise, and Metabolism Council; and the High quality of Care and Outcomes Analysis Interdisciplinary Working Group: the American Academy of Neurology affirms the worth of this guideline. Stroke. 2006;37:1583-1633. doi: 10.1161/01.STR.0000223048.70103.F1
39. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic remedy for secondary prevention of stroke and different thromboembolic occasions in sufferers with stroke or transient ischemic assault and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019;4:198-223. doi:10.1177/2396987319841187
40. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin within the major and secondary prevention of vascular illness: collaborative meta-analysis of particular person participant knowledge from randomised trials. Lancet. 2009;373:1849-1860. doi:10.1016/S0140-6736(09)60503-1
41. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic remedy in atrial fibrillation: American School of Chest Physicians Proof-Primarily based Scientific Follow Pointers (eighth Version). Chest. 2008;133(6 suppl):546S–592S. doi: 10.1378/chest.08-0678
42. Rothwell PM, Algra A, Chen Z, et al. Results of aspirin on threat and severity of early recurrent stroke after transient ischaemic assault and ischaemic stroke: time-course evaluation of randomised trials. Lancet. 2016;388:365-375. doi:10.1016/S0140-6736(16)30468-8